End-to-End Clinical Trial Design in the Agentic Era

About this session

This conversation will explore how agentic AI can transform end-to-end clinical trial design, from protocol development and endpoint selection to country and site strategy, patient recruitment planning, and operational readiness. It examines where specialized AI agents can augment cross-functional teams, automate complex work processes, and enable faster, more adaptive decision-making—ultimately with a goal of accelerating overall drug development timelines while preserving scientific rigor, regulatory alignment, data quality, and human oversight.

Speaker

• 

  Bryan Feldman

  Senior Director, Business Technology for Clinical Development, Regulatory Affairs, and R&D QA · AbbVie

  Speaker